Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval
FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease that can progress to end-stage renal failure. Competition looms from Vertex Pharmaceuticals, on track to receive a November regulatory decision for a drug designed to block the same two proteins.
Pearl Health Lands $110M to Support Value-Based Care for Medicare Patients
Pearl's $110 million raise includes a $50 million equity investment led by Andreessen Horowitz with participation from Viking Global Investors, AlleyCorp and Ulysses Capital, as well as a $60 million debt facility led by Trinity Capital.
Organ-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On It
Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA's move away from reliance on animal testing towards organoid, organ-on-a-chip, and other in silico technologies. A Connecticut startup believes whole-organ testing should be an essential part of this mix.
presented by
What Can Payers Do to Improve AI Readiness?
A webinar by Verato and MedCity News on July 22 will explore how building a trusted data foundation that connects the healthcare ecosystem can improve how payers deploy AI.
Why the Future of IDR Depends on Smarter Technology
Focusing on fringe cases of abuse misses a more immediate and arguably more pervasive problem: many provider organizations are not getting the access to IDR they’re entitled to because the process is too difficult to navigate effectively at scale.